Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial ; volume:19 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
Archives of osteoporosis ; 19, Heft 1 (26.11.2024), 1-9, 12.2024

Creator: Baek, Seungjin
Ahn, Seong Hee
Hong, Namki
Seo, Da Hea
Hong, Seongbin
Rhee, Yumie

Contributor: SpringerLink (Online service)

DOI: 10.1007/s11657-024-01480-6

URN: urn:nbn:de:101:1-2502272234379.124014466507

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:20 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Baek, Seungjin
Ahn, Seong Hee
Hong, Namki
Seo, Da Hea
Hong, Seongbin
Rhee, Yumie
SpringerLink (Online service)

Other Objects (12)

Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Quality of life in post-menopausal osteoporosis

Association between blood cadmium levels and the risk of osteopenia and osteoporosis in Korean post-menopausal women

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Concerns on modeling postmenopausal osteoporosis on young female rats

$Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women$

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis

Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Quality of life in post-menopausal osteoporosis

Association between blood cadmium levels and the risk of osteopenia and osteoporosis in Korean post-menopausal women

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Concerns on modeling postmenopausal osteoporosis on young female rats

$Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women$

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis

Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Quality of life in post-menopausal osteoporosis

Association between blood cadmium levels and the risk of osteopenia and osteoporosis in Korean post-menopausal women

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Concerns on modeling postmenopausal osteoporosis on young female rats

$Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women$

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Quality of life in post-menopausal osteoporosis

Association between blood cadmium levels and the risk of osteopenia and osteoporosis in Korean post-menopausal women

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Concerns on modeling postmenopausal osteoporosis on young female rats

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis

Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Quality of life in post-menopausal osteoporosis

Association between blood cadmium levels and the risk of osteopenia and osteoporosis in Korean post-menopausal women

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Concerns on modeling postmenopausal osteoporosis on young female rats

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis

Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Quality of life in post-menopausal osteoporosis

Association between blood cadmium levels and the risk of osteopenia and osteoporosis in Korean post-menopausal women

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Concerns on modeling postmenopausal osteoporosis on young female rats

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis

Related objects

Reset password